Quality Payment

# Merit-based Incentive Payment System (MIPS)

2025 Eligible Measure Applicability (EMA) and Denominator Reduction User Guide: Quality Performance Category in Traditional MIPS





## **Table of Contents**

How To Use This Guide	<u>3</u>
EMA and Specialty Set Denominator Reductions	<u>5</u>
Help, Resources, and Version History	<u>11</u>
Appendix A	<u>15</u>
Appendix B	<u>19</u>

**Purpose:** This resource reviews the denominator reduction process available to clinicians, groups, virtual groups, and APM Entities with fewer than 6 measures available for reporting traditional MIPS.

**Already know what MIPS is?** Skip ahead by clicking the links in the Table of Contents.



## Quality Payment

## How to Use This Guide

## How to Use This Guide (Continued)

Please Note: This guide was prepared for informational purposes only and isn't intended to grant rights or impose obligations. The information provided is only intended to be a general summary. It isn't intended to take the place of the written law, including the regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

#### **Table of Contents**

The Table of Contents is interactive. Click on a Chapter in the Table of Contents to read that section. 
You can also click on the icon on the bottom left to go back to the Table of Contents.

#### Hyperlinks

Hyperlinks to the <u>Quality Payment Program</u> <u>website</u> are included throughout the guide to direct the reader to more information and resources.



Quality Payment

# EMA and Specialty Set Denominator Reductions

#### EMA AND SPECIALTY SET DENOMINATOR REDUCTIONS

### What Are the 2025 Performance Period Submission Requirements for the Quality Performance Category in Traditional MIPS?

The traditional MIPS quality performance category data submission requirements are:

- Submit 6 quality measures (195 measures finalized in MIPS plus hundreds of Qualified Clinical Data Registry (QCDR) measures are available for reporting), or
- Submit a complete specialty measure set.

1 of these quality measures must be an outcome measure. If an outcome measure isn't available, then you must submit a high priority measure.

# What Happens if I Don't Meet These Requirements?

If you submit fewer than 6 measures, or you submit 6 or more measures but no outcome or high priority measure, we apply a denominator reduction process to determine if you reported all measures related to a clinical topic or within a specialty set.

If we determine that you could have reported more measures, you'll receive 0 out of 10 points for each required measure that isn't submitted.

The denominator reduction process is only applied to clinicians, groups, virtual groups, or APM Entities that:

 Report their quality measures for traditional MIPS through Medicare Part B claims or submit MIPS CQMs.

We don't apply the denominator reduction process to submissions that include QCDR measures or electronic clinical quality measures (eCQMs).

## Quality Payment

### **Denominator Reduction Paths**

There are 2 types of denominator reductions:

Eligible Measure Applicability (EMA) Process

Looks at measures related to a clinical topic Specialty Measure Set Denominator Reduction Process

Applies to specialty measure sets with fewer than 6 measures

#### EMA AND SPECIALTY SET DENOMINATOR REDUCTIONS

## How Do Denominator Reductions Work?

- 1. We check that you reported Medicare Part B claims measures or MIPS CQMs.
- 2. We determine whether you reported all the measures available for your chosen collection type related to a clinical topic or in a specialty measure set with fewer than 6 measures.

Appendix A identifies the measures we have identified as related to specific clinical topics.

<u>Appendix B</u> identifies the specialty measure sets with fewer than 6 measures available for the Medicare Part B claims or MIPS CQM collection types.

## How Can Denominator Reductions Affect My Quality Performance Category Score?

Quality Data You Submitted	Impact to Quality Performance Category Score		
Fewer than 6 measures:	You may qualify for a <b>denominator reduction</b> . This means we would reduce the number of measures you're required to report. Your denominator for the quality performance category is 10 x the number of required measures.	cc m de wi	lea om iini enc ill e oin
No outcome or high priority measure	You may qualify to <b>earn achievement points for all 6 submitted</b> <b>measures.</b> This means you wouldn't receive 0 out of 10 points for the unsubmitted outcome or high priority measure.		

Measures that don't meet data completeness (75%) or case minimum requirements (20 denominator eligible instances) will earn 0 out of 10 points (3 points for small practices).

## No Denominator Eligible Instances (MIPS CQMs)

If the MIPS eligible clinician or group doesn't have any denominator eligible instances for a measure related to the clinical topic (or in a specialty measure set with fewer than 6 measures available for your chosen collection type), submit the MIPS CQM as 0/0 (Os in the numerator and denominator). We'll exclude these measures from the quality performance score denominator.

If there are any denominator eligible instances, the measure must be reported as usual.

No supporting documentation is required at submission, as you must attest that data you submit has been validated and is true, accurate, and complete to the best of your knowledge. If you're selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate, and complete.

## When Will I See Scoring Changes from a Denominator Reduction Applied to My Submission?

Denominator reductions will be applied to your 2025 quality score when we release final scores in Summer 2026.

- If you report MIPS CQMs and your submission qualifies for a denominator reduction, you'll see related messaging during submission.
- Small practices reporting Medicare Part B claims measures won't see this messaging during submission because we don't perform this evaluation on Medicare Part B claims measures until the submission period closes. This timeline lets us ensure that all claims have been processed and attributed to your quality submission.

If you reported all the measures (Medicare Part B claims or MIPS CQMs) available to you and don't see a denominator reduction when final scores are released in Summer 2026, please contact the QPP Service Center as you may need to submit a targeted review. The 2025 targeted review period will open when MIPS final scores are released and remain open for 30 days after MIPS payment adjustments are released.

# Can We Choose to Submit Only the Measures Related to a Clinical Topic as Defined in <u>Appendix A</u>?

No. You should submit all quality measures that apply to your scope of practice and not limit your submission to those measures contained within the clinical topic. The EMA process was established to support clinicians and groups who may not have 6 quality measures available for, and applicable, to their practice.

# When Are the Specialty Measure Sets and EMA Clinically Related Measures Updated?

Every year, we update the specialty measure sets through the rulemaking process. We receive stakeholder input through the annual specialty set solicitation process and public comments made in the Federal Register.

Every year, we update the measures related to a clinical topic (EMA process) through a sub-regulatory process. We get stakeholder input through collaborative review and feedback.



Quality Payment

# Help, Resources, and Version History

#### HELP, RESOURCES, AND VERSION HISTORY

## Quality Payment

### Where Can You Go for Help?

Contact the Quality Payment Program Service Center by email at <u>QPP@cms.hhs.gov</u>, by creating a <u>QPP Service Center ticket</u>, or by phone at 1-866-288-8292 (Monday through Friday, 8 a.m. - 8 p.m. ET). To receive assistance more quickly, please consider calling during nonpeak hours—before 10 a.m. and after 2 p.m. ET.

 People who are deaf or hard of hearing can dial 711 to be connected to a TRS Communications Assistant. Visit the <u>Quality Payment Program</u> website for other <u>help and support</u> information, to learn more about <u>MIPS</u>, and to check out the resources available in the <u>Quality</u> <u>Payment Program Resource Library</u>.

Visit the <u>Small Practices page</u> of the Quality Payment Program website where you can **sign up for the monthly QPP Small Practices Newsletter** and find resources and information relevant for small practices.

#### HELP, RESOURCES, AND VERSION HISTORY

## **Additional Resources**

The following resources are available on the <u>QPP Resource Library</u>:

- 2025 Quality Quick Start Guide (PDF, 2MB)
- 2025 MIPS Quality Measures List (XLSX, 803KB)



#### HELP, RESOURCES, AND VERSION HISTORY



## **Version History**

If we need to update this document, changes will be identified here.

DATE	DESCRIPTION
06/20/2025	Original Posting.



Appendix A: MIPS Clinically Related Measures Grouped by Clinical Topic

#### APPENDIX A: MIPS CLINICALLY RELATED MEASURES GROUPED BY CLINICAL TOPIC (TABLE 1)

Clinical Topic	MIPS CQMs	Medicare Part B Claims
Anesthesiology Care	<ul> <li>404: Anesthesiology Smoking Abstinence</li> <li>424: Perioperative Temperature Management</li> <li>430: Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination</li> <li>Therapy</li> <li>463: Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)</li> </ul>	Not Applicable
CABG Care	<ul> <li>164: Coronary Artery Bypass Graft (CABG): Prolonged Intubation</li> <li>167: Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure</li> <li>168: Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration</li> <li>445: Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)</li> </ul>	Not Applicable
Cardiac Stress Imaging	<b>322</b> : Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients	Not Applicable
Cataract Care	<ul> <li>191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery</li> <li>303: Cataracts: Improvement in Patient's Visual Function within 90 Days Following</li> <li>Cataract Surgery</li> <li>304: Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery</li> <li>389: Cataract Surgery: Difference Between Planned and Final Refraction</li> </ul>	Not Applicable

(C) Denotes a change to the measures available for the clinical topic (N) Denotes a new clinical topic.

**Note:** MIPS CQMs that don't have any eligible instances for a clinically related measure should be submitted as 0/0. No supporting documentation is required at submission, as you must attest that data you submit has been validated and is true, accurate, and complete to the best of your knowledge. If you're selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate, and complete.

#### APPENDIX A: MIPS CLINICALLY RELATED MEASURES GROUPED BY CLINICAL TOPIC (TABLE 2)

Clinical Topic	MIPS CQMs	Medicare Part B Claims
Computed Tomography (C)	<ul> <li>360: Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies</li> <li>364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow- up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines</li> <li>405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients</li> </ul>	<ul> <li>405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients</li> </ul>
Diagnostic Imaging	145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy	<b>145</b> : Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy
Endoscopy and Polyp Surveillance (C)	<ul> <li>185: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use</li> <li>320: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients</li> </ul>	<b>320:</b> Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
Interventional Radiology (C)	<ul> <li>145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy</li> <li>413: Door to Puncture Time for Endovascular Stroke Treatment</li> <li>465: Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries</li> </ul>	<b>145:</b> Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy

(C) Denotes a change to the measures available for the clinical topic

(N) Denotes a new clinical topic.

#### APPENDIX A: MIPS CLINICALLY RELATED MEASURES GROUPED BY CLINICAL TOPIC (TABLE 3)

Clinical Topic	MIPS CQMs	Medicare Part B Claims
Pathology 1	<ul> <li>249: Barrett's Esophagus</li> <li>250: Radical Prostatectomy Pathology Reporting</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology Specimens)</li> <li>396: Lung Cancer Reporting (Resection Specimens)</li> <li>397: Melanoma Reporting</li> </ul>	<ul> <li>249: Barrett's Esophagus</li> <li>250: Radical Prostatectomy</li> <li>Pathology Reporting</li> <li>395: Lung Cancer Reporting</li> <li>(Biopsy/Cytology Specimens)</li> <li>396: Lung Cancer Reporting</li> <li>(Resection Specimens)</li> <li>397: Melanoma Reporting</li> </ul>
Pathology 2	<ul> <li>249: Barrett's Esophagus</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology Specimens)</li> <li>397: Melanoma Reporting</li> <li>491: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing</li> <li>Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel</li> <li>Carcinoma</li> </ul>	<ul> <li>249: Barrett's Esophagus</li> <li>395: Lung Cancer Reporting</li> <li>(Biopsy/Cytology Specimens)</li> <li>397: Melanoma Reporting</li> </ul>
Pathology 3 (N)	<ul> <li>249: Barrett's Esophagus</li> <li>250: Radical Prostatectomy Pathology Reporting</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology Specimens)</li> <li>396: Lung Cancer Reporting (Resection Specimens)</li> <li>491: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing</li> <li>Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel</li> <li>Carcinoma</li> </ul>	<ul> <li>249: Barrett's Esophagus</li> <li>250: Radical Prostatectomy</li> <li>Pathology Reporting</li> <li>395: Lung Cancer Reporting</li> <li>(Biopsy/Cytology Specimens)</li> <li>396: Lung Cancer Reporting</li> <li>(Resection Specimens)</li> </ul>

(C) Denotes a change to the measures available for the clinical topic

(N) Denotes a new clinical topic.

#### APPENDIX A: MIPS CLINICALLY RELATED MEASURES GROUPED BY CLINICAL TOPIC (TABLE 4)

Clinical Topic	MIPS CQMs	Medicare Part B Claims
Pathology 4 (N)	<ul> <li>249: Barrett's Esophagus</li> <li>397: Melanoma Reporting</li> <li>440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician</li> </ul>	<b>249:</b> Barrett's Esophagus <b>397:</b> Melanoma Reporting
Pathology – Skin Cancer	<b>397:</b> Melanoma Reporting <b>440:</b> Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician	<b>397:</b> Melanoma Reporting
Surgical Care	<ul> <li>355: Unplanned Reoperation within the 30 Day Postoperative Period</li> <li>357: Surgical Site Infection (SSI)</li> <li>358: Patient-Centered Surgical Risk Assessment and Communication</li> </ul>	Not applicable

(C) Denotes a change to the measures available for the clinical topic

(N) Denotes a new clinical topic.



Quality Payment

Appendix B: Specialty Measure Sets with Fewer than 6 Measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 1)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Allergy/ Immunology	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Anesthesiology	<ul> <li>404: Anesthesiology Smoking Abstinence</li> <li>424: Perioperative Temperature Management</li> <li>430: Prevention of Post-Operative Nausea and Vomiting (PONV) –</li> <li>Combination Therapy</li> <li>463: Prevention of Post-Operative Vomiting (POV) – Combination Therapy</li> <li>(Pediatrics)</li> <li>477: Multimodal Pain Management</li> </ul>	Not Applicable

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

(N) Denotes specialty sets <u>newly</u> identified as having fewer than 6 measures for the MIPS CQM and/or Medicare Part B claims measure collection types

**Note:** MIPS CQMs that don't have any eligible instances for a clinically related measure should be submitted as 0/0. No supporting documentation is required at submission, as you must attest that data you submit has been validated and is true, accurate, and complete to the best of your knowledge. If you're selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate, and complete.

When reporting specialty measure sets, you're only accountable for the measures available through your chosen collection type for the specialty measure set. For example:

- The Cardiology specialty set is included in this appendix for the Medicare Part B claims measure collection type because only 4 of the 27 measures can be reported through Medicare Part B claims; however, all 27 measures can be reported as MIPS CQMs.
- The Hospitalist specialty set includes 1 measure if you're reporting Medicare Part B claims measures, and 4 measures if you're reporting MIPS CQMs.

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 2)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims	
Audiology (N)	Not Applicable	134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan	
		181: Elder Maltreatment Screen and Follow-Up Plan	
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
		261: Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	
Cardiology	Not Applicable	047: Advance Care Plan	
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
		236: Controlling High Blood Pressure	
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	
Certified Nurse	Not Applicable	047: Advance Care Plan	
Midwives		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
Clinical Social Work	Not Applicable	047: Advance Care Plan	
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan	
		181: Elder Maltreatment Screen and Follow-Up Plan	
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 3)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Dermatology	Not Applicable	<ul> <li>226: Preventive Care and Screening Tobacco Use: Screening and Cessation Intervention</li> <li>317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented</li> </ul>
Diagnostic Radiology (C)	<ul> <li>145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy</li> <li>360: Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies</li> <li>364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines</li> <li>405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients</li> </ul>	<ul> <li>145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy</li> <li>405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients</li> </ul>
Electrophysiology	<ul> <li>392: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation</li> <li>393: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision</li> </ul>	Not Applicable

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 4)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
(C)		181: Elder Maltreatment Screen and Follow-Up Plan
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Gastroenterology	Not Applicable	047: Advance Care Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
		<b>320:</b> Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
General Surgery	Not Applicable	047: Advance Care Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 5)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Geriatrics (N)	Not Applicable	<b>039:</b> Screening for Osteoporosis for Women Aged 65 – 85 Years of Age
		047: Advance Care Plan
		<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		181: Elder Maltreatment Screen and Follow-Up Plan
Hospitalists	<b>005</b> : Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	047: Advance Care Plan
	<b>008:</b> Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	
	047: Advance Care Plan	
	<b>130:</b> Documentation of Current Medications in the Medical Record	
Infectious Disease	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Interventional Radiology	Not Applicable	<b>145:</b> Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 6)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Mental/Behavioral Health	Not Applicable	134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Nephrology	Not Applicable	001: Diabetes: Glycemic Status Assessment Greater Than 9%
		047: Advance Care Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Neurology (N)	Not Applicable	047: Advance Care Plan
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Neurosurgical	Not Applicable	<b>226</b> : Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 7)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Nutrition/	Not Applicable	001: Diabetes: Glycemic Status Assessment Greater Than 9%
Dietician		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Obstetrics/Gynecology	Not Applicable	039: Screening for Osteoporosis for Women Aged 65 – 85 Years of Age
(N)		047: Advance Care Plan
		236: Controlling High Blood Pressure
		418: Osteoporosis Management in Women Who Had A Fracture
		<b>422:</b> Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury
Oncology	Not Applicable	047: Advance Care Plan
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		250: Radical Prostatectomy Pathology Reporting
		317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Ophthalmology	Not Applicable	<b>141:</b> Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 8)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Optometry (N)	117: Diabetes: Eye Exam	226: Preventive Care and Screening: Tobacco Use: Screening and Cessation
	<b>130:</b> Documentation of Current Medications in the Medical Record	Intervention
	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
	<b>238:</b> Use of High-Risk Medications in Older Adults	
	<b>374:</b> Closing the Referral Loop: Receipt of Specialist Report	
Otolaryngology (C)	Not Applicable	047: Advance Care Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Pathology	Not Applicable	249: Barrett's Esophagus
		250: Radical Prostatectomy Pathology Reporting
		<b>395:</b> Lung Cancer Reporting (Biopsy/Cytology Specimens)
		<b>396:</b> Lung Cancer Reporting (Resection Specimens)
		<b>397:</b> Melanoma Reporting

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 9)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Pediatrics	Not Applicable	<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Physical Medicine (C)	Not Applicable	047: Advance Care Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Physical Therapy/ Occupational Therapy	Not Applicable	<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan
(C)		181: Elder Maltreatment Screen and Follow-Up Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 10)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Plastic Surgery	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317</b> : Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Podiatry (C)	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Preventive Medicine (N)	Not Applicable	<b>001:</b> Diabetes: Glycemic Status Assessment Greater Than 9%
		<b>024:</b> Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older
		<b>039:</b> Screening for Osteoporosis for Women Aged 65 – 85 Years of Age
		047: Advance Care Plan
		<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 11)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Pulmonology	Not Applicable	047: Advance Care Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		236: Controlling High Blood Pressure
Radiation Oncology (C)	<b>102:</b> Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
	<b>143:</b> Oncology: Medical and Radiation – Pain Intensity Quantified	
	<b>144:</b> Oncology: Medical and Radiation – Plan of Care for Pain	
	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
	508: Adult COVID-19 Vaccination Status	
Skilled Nursing Facility	Not Applicable	047: Advance Care Plan
(C)		181: Elder Maltreatment Screen and Follow-Up Plan
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 12)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Speech Language	Not Applicable	134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
Pathology		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Thoracic Surgery	Not Applicable	047: Advance Care Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Urgent Care (N)	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Urology <del>(C)</del>	Not Applicable	047: Advance Care Plan
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

#### APPENDIX B: SPECIALTY MEASURE SETS WITH FEWER THAN 6 MEASURES (TABLE 13)

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Vascular Surgery	Not Applicable	047: Advance Care Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		236: Controlling High Blood Pressure
		317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up
		Documented

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures